LUNG CANCER NON-SMALL CELL STAGE IV

Clinical trials for LUNG CANCER NON-SMALL CELL STAGE IV explained in plain language.

Never miss a new study

Get alerted when new LUNG CANCER NON-SMALL CELL STAGE IV trials appear

Sign up with your email to follow new studies for LUNG CANCER NON-SMALL CELL STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Common aspirin may boost power of leading lung cancer drug

Disease control Completed

This study tested whether adding low-dose aspirin to the standard lung cancer drug osimertinib could help patients live longer without their cancer getting worse. It involved 216 adults with advanced, EGFR-positive non-small cell lung cancer who were starting first-line treatment…

Matched conditions: LUNG CANCER NON-SMALL CELL STAGE IV

Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

LUNG CANCER NON-SMALL CELL STAGE IV

Get alerted when new LUNG CANCER NON-SMALL CELL STAGE IV trials appear

Common aspirin may boost power of leading lung cancer drug